Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | E562_L576del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT E562_L576del results in the deletion of 15 amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 562 to 576 (PMID: 16226710). E562_L576del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT E562_L576del KIT mutant KIT exon11 KIT exon 11 del KIT E562_L576del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727452_54727496del45 |
cDNA | c.1684_1728del45 |
Protein | p.E562_L576del15 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000222.2 | chr4:g.54727452_54727496del45 | c.1684_1728del45 | p.E562_L576del | RefSeq | GRCh38/hg38 |
NM_001385292.1 | chr4:g.54727461_54727505del45 | c.1684_1728del45 | p.G562_D576del15 | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54727466_54727510del45 | c.1686_1730del45 | p.N562_H576del15 | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727449_54727493del45 | c.1684_1728del45 | p.E562_Q576del15 | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727452_54727496del45 | c.1684_1728del45 | p.E562_L576del15 | RefSeq | GRCh38/hg38 |
NM_001385288.1 | chr4:g.54727461_54727505del45 | c.1684_1728del45 | p.G562_D576del15 | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727452_54727496del45 | c.1684_1728del45 | p.E562_L576del15 | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54727466_54727510del45 | c.1686_1730del45 | p.N562_H576del15 | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54727449_54727493del45 | c.1684_1728del45 | p.E562_Q576del15 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT E562_L576del | gastrointestinal stromal tumor | predicted - sensitive | Binimetinib + Imatinib | Case Reports/Case Series | Actionable | In a Phase II trial, Gleevec (imatinib) and Mektovi (binimetinib) combination treatment resulted in an 80% pathological response and 23% RECIST response in a patient with a small bowel gastrointestinal stromal tumor harboring KIT E562_L576del (PMID: 35041493; NCT01991379). | 35041493 |